ClinicalTrials.gg
CompletedNCT01462266Updated Aug 17, 2018Results posted

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

A Phase 3 interventional study of Sitagliptin and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
19th of 197
660 · median 102
Started
2012
with 15 others
Phase 3
74 of 198
none open now
Registered
107th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 74 in phase 3, and was the 107th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus who have inadequate glycemic control on insulin alone or in combination with metformin. The primary hypothesis of this study is that after 24 weeks, sitagliptin reduces the dose of insulin relative to placebo.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • has type 2 diabetes mellitus
  • has one of the following criteria:

    • diagnosed with diabetes after age 40 years and insulin therapy was initiated at least 3 years following diagnosis
    • if diagnosed with diabetes under age 40 years or insulin started earlier than 3 years after diagnosis, has a fasting C-peptide greater than 0.7 ng/mL
  • must be at least 18 years of age and less than or equal to 80 years of age (for participants in India: must be at least 18 years of age and less than or equal to 65 years of age)
  • on a stable regimen of insulin for at least 10 weeks with or without metformin (at least 1500 mg/day) and/or sulfonylurea for at least 10 weeks
  • is highly unlikely to become pregnant (not of or agrees to remain abstinent or use (or have their partner use) an acceptable method of during the study and for 14 days after the last dose of study medication

Exclusion criteria

Exclusion Criteria:

  • has been treated with a dipeptidyl peptidase IV (DPP-4) inhibitor, a thiazolidinedione (TZD), or a glucagon-like peptide-1 (GLP-1) mimetic or analogue, within the past 12 weeks
  • currently on treatment with daily use (one or more injections per day) of a

pre-prandial short-acting or rapid-acting insulin alone or as part of a basal/bolus insulin regimen

  • has symptomatic hyperglycemia that requires immediate initiation, adjustment, or addition of antihyperglycemic therapy
  • has a history of 2 or more episodes of hypoglycemia resulting in seizure,

coma, or loss of consciousness, - or - has had recurrent (≥3 times per week) episodes of hypoglycemia over the past 8 weeks

  • has a history of ketoacidosis
  • is not appropriate for or does not agree to target a fasting glucose of 72-100 mg/dL [4.0-5.6 mmol/L]
  • is on or likely to require treatment with
  • has undergone a surgical procedure within 4 weeks or has planned major surgery during the study
  • is currently being treated for hyperthyroidism or is on thyroid hormone

therapy and has not been on a stable dose for at least 6 weeks

  • has a history of active liver disease (other than non-alcoholic hepatic

steatosis)

  • has had new or worsening signs or symptoms of coronary heart disease or

congestive heart failure within the past 3 months, or has any of the following

disorders within the past 3 months:

  • acute coronary syndrome
  • coronary artery intervention
  • stroke or transient ischemic neurological disorder

    • has a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 90 mm Hg
    • has (HIV)
    • has severe peripheral vascular disease
    • has a hematological disorder
    • has a history of that is less than 5 years from study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
    • has a positive urine pregnancy test
    • is pregnant or breast-feeding, or is expecting to conceive or donate eggs

during the study

  • a user of recreational or illicit drugs or has had a recent history of drug abuse
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
660 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin 100 mg once daily

    Drug: Sitagliptin · Biological: Insulin Glargine · Drug: Metformin

  • Placebo comparator
    Placebo

    Placebo to sitagliptin once daily

    Drug: Comparator: Placebo · Biological: Insulin Glargine · Drug: Metformin

Interventions

  • Sitagliptin 100 mg tablet once daily for 24 weeks

    Also known as: Januvia

  • DrugComparator: Placebo

    Placebo to sitagliptin once daily for 24 weeks

  • Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.

  • Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Daily Insulin Dose at Week 24

    Change in daily insulin dose following 24 weeks of therapy (i.e., daily insulin dose at Week 24 minus daily insulin dose at baseline)

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C) at Week 24

    A1C is measured as the percentage of glycosylated hemoglobin. Change in A1C following 24 weeks of therapy (i.e., A1C at Week 24 minus A1C at baseline)

    Time frame: Baseline and Week 24

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    Change in FPG (before breakfast) following 24 weeks of therapy (i.e., FPG at Week 24 minus FPG at baseline)

    Time frame: Baseline and Week 24

  3. Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study

    The fasting glucose target was defined as 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L).

    Time frame: Up to 24 weeks

  4. Time to Achieve the Fasting Glucose Target

    Fasting glucose target 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L). This analysis was the Kaplan-Meier estimated 50th percentile of time (days) to first attainment of target.

    Time frame: Up to 24 weeks

07

Results

Posted Apr 8, 2014

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started330330
Treated329329
Completed295303
Not completed3527
Withdrew: Adverse event76
Withdrew: Death21
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up43
Withdrew: Non-compliance with study drug30
Withdrew: Creatinine and egfr, excluded medication84
Withdrew: Physician decision25
Withdrew: Protocol violation13
Withdrew: Withdrawal by subject72
Withdrew: Screen failure11

Outcome measures

PrimaryChange From Baseline in Daily Insulin Dose at Week 24

Change in daily insulin dose following 24 weeks of therapy (i.e., daily insulin dose at Week 24 minus daily insulin dose at baseline)

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · International Units (IU)
Change From Baseline in Daily Insulin Dose at Week 24
International Units (IU)SitagliptinPlacebo
Change From Baseline in Daily Insulin Dose at Week 2419.0 ± 19.623.8 ± 24.0
Statistical analysis
  • Sitagliptin vs Placebo · Longitudinal data analysis · p = 0.009 · Mean difference (final values): -4.7 · 95% CI -8.3 to -1.2Adjusting for participant's use of metformin at Visit 1/Screening Visit (i.e., on metformin, or not on metformin)
SecondaryChange From Baseline in Hemoglobin A1c (A1C) at Week 24

A1C is measured as the percentage of glycosylated hemoglobin. Change in A1C following 24 weeks of therapy (i.e., A1C at Week 24 minus A1C at baseline)

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent of total hemoglobin
Change From Baseline in Hemoglobin A1c (A1C) at Week 24
Percent of total hemoglobinSitagliptinPlacebo
Change From Baseline in Hemoglobin A1c (A1C) at Week 24-1.31 ± 0.98-0.87 ± 1.10
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Change in FPG (before breakfast) following 24 weeks of therapy (i.e., FPG at Week 24 minus FPG at baseline)

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mg/dLSitagliptinPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-55.5 ± 52.0-44.8 ± 62.4
SecondaryPercent of Participants Achieving Fasting Glucose Target at Any Time During the Study

The fasting glucose target was defined as 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L).

Time frame:
Up to 24 weeks
Reported as:
Number · Percentage of participants
Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study
Percentage of participantsSitagliptinPlacebo
Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study77.4 (72.6 to 82.2)74.1 (69.0 to 79.2)
SecondaryTime to Achieve the Fasting Glucose Target

Fasting glucose target 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L). This analysis was the Kaplan-Meier estimated 50th percentile of time (days) to first attainment of target.

Time frame:
Up to 24 weeks
Reported as:
Median · Days to first attainment of target
Time to Achieve the Fasting Glucose Target
Days to first attainment of targetSitagliptinPlacebo
Time to Achieve the Fasting Glucose Target78 (64 to 85)90 (80 to 107)

Adverse events

Collected over Up to Week 24 + 14-day follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—13/329 (4%)121/329 (36.8%)
Placebo—12/329 (3.6%)168/329 (51.1%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventSitagliptinPlacebo
ThrombocytopeniaBlood and lymphatic system disorders0/3291/329
Acute coronary syndromeCardiac disorders0/3291/329
Acute myocardial infarctionCardiac disorders0/3291/329
Angina pectorisCardiac disorders0/3291/329
Coronary artery diseaseCardiac disorders1/3290/329
Myocardial infarctionCardiac disorders1/3291/329
Chest painGeneral disorders1/3290/329
HypersensitivityImmune system disorders0/3291/329
Appendicitis perforatedInfections and infestations1/3290/329
CellulitisInfections and infestations1/3291/329
Most frequent other events
Most frequent other events
EventSitagliptinPlacebo
HypoglycaemiaMetabolism and nutrition disorders93/329144/329
NasopharyngitisInfections and infestations13/32926/329
DiarrhoeaGastrointestinal disorders17/32911/329
Urinary tract infectionInfections and infestations14/32917/329

Baseline characteristics

One participant in both the Sitagliptin group and Placebo group was randomized in error and did not receive study medication.

Age, Continuous
Age, Continuous(Years)SitagliptinPlaceboTotal
Mean59.3 ± 8.958.3 ± 9.758.8 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female178165343
Male151164315
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Mathieu C, Shankar RR, Lorber D, Umpierrez G, Wu F, Xu L, Golm GT, Latham M, Kaufman KD, Engel SS. A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Diabetes Ther. 2015 Jun;6(2):127-42. doi: 10.1007/s13300-015-0105-3. Epub 2015 Mar 28. PubMed 25820927 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Jun 2013, 16 months.

Results were first posted in Apr 2014, 10 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2011
First posted
Oct 31, 2011
StartActual
Jan 13, 2012
Primary completionActual
Jun 6, 2013
CompletionActual
Jun 7, 2013
Results first posted
Apr 8, 2014
Last update
Aug 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01462266
Responsible party
Sponsor
First posted
Oct 31, 2011
Start date
Jan 13, 2012
Primary completion
Jun 6, 2013
Completion
Jun 7, 2013
Results posted
Apr 8, 2014
Last update
Aug 17, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion